vs
IMMUCELL CORP（ICCC）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Alpha Teknova, Inc.的季度营收约是IMMUCELL CORP的1.8倍（$10.0M vs $5.5M）。IMMUCELL CORP净利率更高（-2.5% vs -47.7%，领先45.1%）。Alpha Teknova, Inc.同比增速更快（7.8% vs -8.4%）。Alpha Teknova, Inc.自由现金流更多（$-810.0K vs $-1.8M）。过去两年IMMUCELL CORP的营收复合增速更高（3.9% vs 3.7%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
ICCC vs TKNO — 直观对比
营收规模更大
TKNO
是对方的1.8倍
$5.5M
营收增速更快
TKNO
高出16.2%
-8.4%
净利率更高
ICCC
高出45.1%
-47.7%
自由现金流更多
TKNO
多$966.5K
$-1.8M
两年增速更快
ICCC
近两年复合增速
3.7%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $10.0M |
| 净利润 | $-139.7K | $-4.8M |
| 毛利率 | 42.9% | 32.5% |
| 营业利润率 | 0.4% | -46.2% |
| 净利率 | -2.5% | -47.7% |
| 营收同比 | -8.4% | 7.8% |
| 净利润同比 | 80.1% | 16.8% |
| 每股收益（稀释后） | $-0.02 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCTKNO
| Q4 25 | — | $10.0M | ||
| Q3 25 | $5.5M | $10.5M | ||
| Q2 25 | $6.4M | $10.3M | ||
| Q1 25 | $8.1M | $9.8M | ||
| Q4 24 | $7.8M | $9.3M | ||
| Q3 24 | $6.0M | $9.6M | ||
| Q2 24 | $5.5M | $9.6M | ||
| Q1 24 | $7.3M | $9.3M |
净利润ICCCTKNO
| Q4 25 | — | $-4.8M | ||
| Q3 25 | $-139.7K | $-4.3M | ||
| Q2 25 | $501.9K | $-3.6M | ||
| Q1 25 | $1.4M | $-4.6M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | $-701.7K | $-7.6M | ||
| Q2 24 | $-1.5M | $-5.4M | ||
| Q1 24 | $-437.9K | $-8.1M |
毛利率ICCCTKNO
| Q4 25 | — | 32.5% | ||
| Q3 25 | 42.9% | 30.7% | ||
| Q2 25 | 43.7% | 38.7% | ||
| Q1 25 | 41.6% | 30.7% | ||
| Q4 24 | 36.5% | 23.0% | ||
| Q3 24 | 26.3% | 0.9% | ||
| Q2 24 | 22.5% | 29.2% | ||
| Q1 24 | 31.6% | 23.8% |
营业利润率ICCCTKNO
| Q4 25 | — | -46.2% | ||
| Q3 25 | 0.4% | -38.4% | ||
| Q2 25 | 8.8% | -32.9% | ||
| Q1 25 | 13.9% | -50.7% | ||
| Q4 24 | 8.0% | -60.7% | ||
| Q3 24 | -9.6% | -77.6% | ||
| Q2 24 | -25.3% | -53.0% | ||
| Q1 24 | -4.1% | -86.0% |
净利率ICCCTKNO
| Q4 25 | — | -47.7% | ||
| Q3 25 | -2.5% | -41.0% | ||
| Q2 25 | 7.8% | -34.7% | ||
| Q1 25 | 17.9% | -47.4% | ||
| Q4 24 | — | -61.7% | ||
| Q3 24 | -11.7% | -79.0% | ||
| Q2 24 | -28.0% | -55.8% | ||
| Q1 24 | -6.0% | -87.2% |
每股收益（稀释后）ICCCTKNO
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.02 | $-0.08 | ||
| Q2 25 | $0.06 | $-0.07 | ||
| Q1 25 | $0.16 | $-0.09 | ||
| Q4 24 | $0.09 | $-0.09 | ||
| Q3 24 | $-0.09 | $-0.15 | ||
| Q2 24 | $-0.20 | $-0.13 | ||
| Q1 24 | $-0.06 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $21.3M |
| 总债务越低越好 | $9.5M | $13.1M |
| 股东权益账面价值 | $29.8M | $68.8M |
| 总资产 | $45.7M | $103.6M |
| 负债/权益比越低杠杆越低 | 0.32× | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资ICCCTKNO
| Q4 25 | — | $21.3M | ||
| Q3 25 | $3.9M | $22.1M | ||
| Q2 25 | — | $24.0M | ||
| Q1 25 | — | $26.3M | ||
| Q4 24 | $3.8M | $30.4M | ||
| Q3 24 | — | $31.7M | ||
| Q2 24 | $1.3M | $18.6M | ||
| Q1 24 | $960.3K | $21.6M |
总债务ICCCTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | $9.5M | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | $8.7M | $13.0M | ||
| Q4 24 | $9.0M | $9.4M | ||
| Q3 24 | $9.4M | $10.9M | ||
| Q2 24 | $9.8M | $12.3M | ||
| Q1 24 | $10.2M | $13.2M |
股东权益ICCCTKNO
| Q4 25 | — | $68.8M | ||
| Q3 25 | $29.8M | $72.7M | ||
| Q2 25 | $29.9M | $76.1M | ||
| Q1 25 | $29.0M | $78.6M | ||
| Q4 24 | $27.5M | $82.4M | ||
| Q3 24 | $26.4M | $87.3M | ||
| Q2 24 | $23.5M | $78.9M | ||
| Q1 24 | $24.6M | $83.4M |
总资产ICCCTKNO
| Q4 25 | — | $103.6M | ||
| Q3 25 | $45.7M | $107.6M | ||
| Q2 25 | $46.7M | $110.5M | ||
| Q1 25 | $45.6M | $114.0M | ||
| Q4 24 | $45.1M | $118.8M | ||
| Q3 24 | $44.4M | $124.1M | ||
| Q2 24 | $41.9M | $115.4M | ||
| Q1 24 | $43.1M | $120.8M |
负债/权益比ICCCTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | 0.32× | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | 0.30× | 0.17× | ||
| Q4 24 | 0.33× | 0.11× | ||
| Q3 24 | 0.36× | 0.12× | ||
| Q2 24 | 0.42× | 0.16× | ||
| Q1 24 | 0.41× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-810.0K |
| 自由现金流率自由现金流/营收 | -32.3% | -8.1% |
| 资本支出强度资本支出/营收 | 10.8% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $715.4K | $-9.8M |
8季度趋势，按日历期对齐
经营现金流ICCCTKNO
| Q4 25 | — | $-462.0K | ||
| Q3 25 | $-1.2M | $-2.0M | ||
| Q2 25 | $1.6M | $-2.1M | ||
| Q1 25 | $1.6M | $-4.1M | ||
| Q4 24 | $-3.1K | $-936.0K | ||
| Q3 24 | $-639.3K | $-2.1M | ||
| Q2 24 | $581.8K | $-2.8M | ||
| Q1 24 | $418.5K | $-6.6M |
自由现金流ICCCTKNO
| Q4 25 | — | $-810.0K | ||
| Q3 25 | $-1.8M | $-2.4M | ||
| Q2 25 | $1.4M | $-2.3M | ||
| Q1 25 | $1.2M | $-4.3M | ||
| Q4 24 | $-199.3K | $-1.5M | ||
| Q3 24 | $-727.7K | $-2.4M | ||
| Q2 24 | $471.0K | $-3.0M | ||
| Q1 24 | $348.1K | $-6.7M |
自由现金流率ICCCTKNO
| Q4 25 | — | -8.1% | ||
| Q3 25 | -32.3% | -22.6% | ||
| Q2 25 | 22.4% | -22.4% | ||
| Q1 25 | 15.4% | -44.0% | ||
| Q4 24 | -2.6% | -16.2% | ||
| Q3 24 | -12.1% | -25.0% | ||
| Q2 24 | 8.6% | -30.7% | ||
| Q1 24 | 4.8% | -71.8% |
资本支出强度ICCCTKNO
| Q4 25 | — | 3.5% | ||
| Q3 25 | 10.8% | 3.7% | ||
| Q2 25 | 2.4% | 2.0% | ||
| Q1 25 | 4.1% | 2.1% | ||
| Q4 24 | 2.5% | 6.1% | ||
| Q3 24 | 1.5% | 3.5% | ||
| Q2 24 | 2.0% | 1.2% | ||
| Q1 24 | 1.0% | 1.2% |
现金转化率ICCCTKNO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.19× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICCC
暂无分部数据
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
